|Other Names||Methyl-CpG-binding domain protein 4, 322-, Methyl-CpG-binding endonuclease 1, Methyl-CpG-binding protein MBD4, Mismatch-specific DNA N-glycosylase, MBD4, MED1|
|Format||Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Mismatch-specific DNA N-glycosylase involved in DNA repair. Has thymine glycosylase activity and is specific for G:T mismatches within methylated and unmethylated CpG sites. Can also remove uracil or 5-fluorouracil in G:U mismatches. Has no lyase activity. Was first identified as methyl-CpG-binding protein.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DNA methylation is the major modification of eukaryoticgenomes and plays an essential role in mammalian development. Humanproteins MECP2, MBD1, MBD2, MBD3, and MBD4 comprise a family ofnuclear proteins related by the presence in each of a methyl-CpGbinding domain (MBD). Each of these proteins, with the exception ofMBD3, is capable of binding specifically to methylated DNA. MBD4may function to mediate the biological consequences of themethylation signal. In addition, MBD4 has protein sequencesimilarity to bacterial DNA repair enzymes and thus may have somefunction in DNA repair. Further, MBD4 gene mutations are detectedin tumors with primary microsatellite-instability (MSI), a form ofgenomic instability associated with defective DNA mismatch repair,and MBD4 gene meets 4 of 5 criteria of a bona fide MIS target gene.
Arora, M., et al. Leukemia 24(8):1470-1475(2010)Thyagarajan, B., et al. Biol. Blood Marrow Transplant. 16(8):1084-1089(2010)Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press :Briggs, F.B., et al. Am. J. Epidemiol. 172(2):217-224(2010)Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.